At Asphalion, we have dedicated this week to showcasing the importance of Development, Medical & Scientific Writing. Our team of expert consultants can keep you stay ahead of market challenges and navigate complex regulatory requirements.
Today, we are bringing the week to a close by putting the spotlight on Orphan Drug Designation (ODD)!
Developing therapies for rare diseases requires more than scientific innovation. It demands a robust regulatory strategy, underpinned by high-quality medical and scientific documentation.
At ASPHALION, we provide Development, Medical & Scientific Writing and Regulatory Affairs support to pharmaceutical and biotechnology companies throughout the development of orphan drugs. Our expertise includes the preparation of Orphan Designation applications; Scientific Advice and Protocol Assistance briefing packages; Paediatric Investigational Plans; clinical and regulatory documentation; responses to Health Authorities, and other key regulatory submissions.
Although both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) offer incentives to encourage orphan drug development, their respective regulatory frameworks can differ significantly. Understanding these differences is essential to developing an effective regulatory strategy.
Explore our carousel to discover how we can support you throughout the Orphan Drug Designation process.
Need help navigating your Regulatory Affairs strategy? Get in touch with us!: [email protected]






